Wealth Enhancement Advisory Services, LLC Fate Therapeutics Inc Transaction History
Wealth Enhancement Advisory Services, LLC
- $49 Billion
- Q1 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 29,909 shares of FATE stock, worth $37,984. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,909Holding current value
$37,984% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
144Shares Held
97MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$16.3 Million1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$13.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$12.8 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$9.9 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$5.45 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $123M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...